Results
author = "SCHEEN, André"
> : "Double-Blind Method"
(x)
Info-congres. Prevention du diabete de type 2 chez le sujet obese: premiers resultats avec l'orlistat dans l'etude XENDOS. Info-congress. Prevention of type 2 diabetes in obese patients: first results with orlistat in the XENDOS study
Author(s) :
Scheen, André
Description :
The results of the XENDOS study were presented by Professor Lars Sjostrom (Gothenburg, Sweden), on August 26, 2002, at the 9th International Congress on Obesity in Sao Paulo, Brazil. XENDOS (XENical in the prevention of Diabetes in Obese Subjects) is a multicentre, randomised, double-blind, placebo-...
Repository :
ORBi (University of Liège)
Language(s) :
French
L'etude clinique du mois. L'etude ADOPT: quel antidiabetique oral initier chez le patient diabetique de type 2? ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?
Author(s) :
Scheen, André
Description :
ADOPT ("A Diabetes Outcome Progression Trial") is a double-blind, controlled clinical trial that aims at assessing the efficacy of rosiglitazone, as compared to metformin or glibenclamide, in maintaining long-term glycaemic control in patients with recently diagnosed type 2 diabetes. It randomized 4...
Repository :
ORBi (University of Liège)
Language(s) :
French
Etude clinique du mois. L'etude DREAM: prevention du diabete de type 2 par le ramipiril et/ou la rosiglitazone chez les personnes dysglycemiques sans maladie cardio-vasculaire. DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease
Author(s) :
Scheen, André
Description :
DREAM ("Diabetes Reduction Assessment with ramipril and rosiglitazone Medication") is a double-blind randomised placebo-controlled clinical trial with a 2-by-2 factorial design aiming to study the effects of an ACE inhibitor (ramipril 15 mg/day) and/or a thiazolidinedione (rosiglitazone 8 mg/day) on...
Repository :
ORBi (University of Liège)
Language(s) :
French
L'etude clinique du mois. NAVIGATOR: essai de prevention des complications cardio-vasculaires et du diabete de type 2 par le valsartan et/ou le nateglinide. NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide
Author(s) :
Scheen, André
Description :
NAVIGATOR ("Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research") is a large international placebo-controlled trial that randomised 9,031 individuals at high risk because of impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors. This t...
Repository :
ORBi (University of Liège)
Language(s) :
French
L'etude clinique du mois. L'etude EUROPA: protection cardio-vasculaire avec le perindopril chez les patients avec coronaropathie stable. Clinical study of the month. The EUROPA study: cardiovascular protection with perindopril in patients with stable coronary heart disease
Description :
The multicentre placebo-controlled double-blind "EUropean trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease" (EUROPA) assessed whether the angiotensin-converting-enzyme inhibitor perindopril reduces cardiovascular risk in a population with stable c...
Repository :
ORBi (University of Liège)
Language(s) :
French
L'etude clinique du mois. ADVANCE: amelioration de la survie et reduction des complications vasculaires et renales avec la combinaison fixe perindopril-indapamide chez le patient diabetique de type 2. [Clinical trial of the month. ADVANCE: improved survival and better vascular and renal outcomes with a fixed combination of perindopril and indapamide in patients with type 2 diabetes]
Description :
The controlled ADVANCE trial compared the incidence of major macrovascular and microvascular complications in 5,569 type 2 diabetic patients randomised to a fixed combination of perindopril and indapamide and in 5,571 patients randomised to placebo, followed for a mean duration of 4.3 years. Compare...
Repository :
ORBi (University of Liège)
Language(s) :
French
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.
Author(s) :
Scheen, André
,
Finer, Nick
,
Hollander, Priscilla
,
Jensen, Michael D
,
Van Gaal, Luc F
Description :
BACKGROUND: Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic overweight or obese patients. The aim of the RIO-Diabetes trial was to assess the efficacy and safety of rimonabant in overweight or obes...
Repository :
ORBi (University of Liège)
Language(s) :
English
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Author(s) :
Van Gaal, Luc F
,
Rissanen, Aila M
,
Scheen, André
,
Ziegler, Olivier
,
Rossner, Stephan
Description :
BACKGROUND: In animal models, cannabinoid-1 receptor (CB1) blockade produces a lean phenotype, with resistance to diet-induced obesity and associated dyslipidaemia. We assessed the effect of rimonabant, a selective CB1 blocker, on bodyweight and cardiovascular risk factors in overweight or obese pat...
Repository :
ORBi (University of Liège)
Language(s) :
English
Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.
Author(s) :
Ruilope, Luis M
,
Despres, Jean-Pierre
,
Scheen, André
,
Pi-Sunyer, Xavier
,
Mancia, Guiseppe
,
Zanchetti, Alberto
,
Van Gaal, Luc
Description :
OBJECTIVE: Rimonabant, the first selective cannabinoid type 1 (CB1) receptor blocker, has been shown to improve multiple cardiometabolic risk factors in overweight/obese patients. This analysis assessed the impact of rimonabant on blood pressure in the pooled population from four large trials with s...
Repository :
ORBi (University of Liège)
Language(s) :
English
Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER.
Author(s) :
Mogensen, Carl Erik
,
Viberti, Giancarlo
,
Halimi, Serge
,
Ritz, Eberhard
,
Ruilope, Luis
,
Jermendy, Gyorgy
,
Widimsky, Jiri
Description :
Microalbuminuria in diabetes is a risk factor for early death and an indicator for aggressive blood pressure (BP) lowering. We compared a combination of 2 mg perindopril/0.625 mg indapamide with enalapril monotherapy on albumin excretion rate (AER) in patients with type 2 diabetes, albuminuria, and ...
Repository :
ORBi (University of Liège)
Language(s) :
English